SCHEMBL1360036

SCHEMBL1360036

COc1ccccc1OCCCc1oc(-n2cnc(-c3ccccc3)c2-c2ccccc2)nc1-c1ccc(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.37
PDE10A Q9Y233 2/20 0.37
MAPT P10636 3/20 0.36
TAAR1 Q96RJ0 1/20 0.35
FAAH O00519 4/20 0.35
TP53 P04637 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
TSHR P16473 3/20 0.34
MAPK1 P28482 2/20 0.34
DHPS P49366 1/20 0.34
THRB P10828 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALOX15 P16050 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361176 0.87 RAB9A (0.40) POLBMAPTTP53TSHRMAPK1
SCHEMBL962882 0.82 MAPT (0.36) POLBMAPTTP53L3MBTL1TSHR
SCHEMBL1362811 0.81 GCGR (0.35) POLBMAPTTP53L3MBTL1TSHR
SCHEMBL1362126 0.80 MAPT (0.46) MAPTTSHRTHRBALDH1A1
SCHEMBL1363245 0.80 GRM7 (0.40) POLBPDE10AMAPTTAAR1TP53
SCHEMBL1361453 0.80 CYP3A4 (0.38) POLBMAPTTP53L3MBTL1TSHR
SCHEMBL1360286 0.80 GCGR (0.37) POLBMAPTTP53L3MBTL1TSHR
SCHEMBL1361698 0.80 MAPT (0.41) POLBMAPTTP53L3MBTL1TSHR
SCHEMBL1360017 0.80 MAPT (0.36) POLBMAPTTP53L3MBTL1TSHR
SCHEMBL1361683 0.79 SLC2A1 (0.44) MAPTL3MBTL1TSHRALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed
EP-1206472-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT Takeda Chemical Industries, Ltd. (JP) 2002-05-22 EP disclosed
WO-2001014372-A2 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 POLB 4273/4885PDE10A 1702/4885MAPT 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.